Novanta reported second quarter 2026 results for the period ended July 3, 2026, with GAAP revenue up 10% to $266 million and GAAP net income of $12.5 million, compared with $4.5 million a year earlier. The company also updated its third quarter and full year 2026 guidance to include the recently closed Riverpoint Medical acquisition, which it says roughly doubles its recurring medical consumables business.
GAAP diluted EPS was $0.30 versus $0.12 a year earlier; Adjusted Diluted EPS rose 17.1% to $0.89.
Adjusted EBITDA rose 16.4% to $60.7 million, with an Adjusted EBITDA margin of 22.8%.
Q3 2026 guidance: GAAP revenue of $300 million to $304 million and Adjusted Diluted EPS of $0.95 to $1.00.
Full year 2026 guidance: GAAP revenue of $1,130 million to $1,140 million and Adjusted Diluted EPS of $3.68 to $3.74.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Novanta's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$980.60M
+3.3%
$1.47
-16.9%
5.5%
FY2024
$949.25M
+7.7%
$1.77
-12.4%
6.8%
FY2023
$881.66M
+2.4%
$2.02
-1.9%
8.3%
FY2022
$860.90M
+21.8%
$2.06
+46.1%
8.6%
FY2021
$706.79M
+19.7%
$1.41
+12.8%
7.1%
Frequently asked questions
When is Novanta's next earnings date?
Novanta (NOVT) is scheduled to report on Monday, November 09, 2026 after the market closes. Analysts expect EPS of $0.97.
What did Novanta earn last quarter?
For the quarter ended Jul 2026, Novanta reported diluted EPS of $0.30 (+150.0% year over year) on revenue of $265.81M (+10.3%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.